Pharmaceutical giant Pfizer said yesterday on improving the forecast of earnings growth to 2.01-2.07 dollars per share against 1.95-2.05 per share previously. Recently, the company had to overcome the problems associated with the expiry of patents. The results also were negatively impacted by the strong dollar. As a result, the company announced earnings of 2.63 billion dollars in the second quarter against 2.91 billion in the same period last year. Given the strong market position and strong financial results, we expect growth of the company's shares at 21-25% per annum in the medium term.